Celerion Expands UK Phase 1 Clinical Research Operations With New Agreement to Relocate to Queen’s University Belfast’s iREACH Health – Clinical Research Innovation Center
Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health. This state-of-the-art clinical research center, led by Queen’s University Belfast, in partnership with the Belfast Health and Social Care Trust, is set to become a cornerstone of Northern Ireland’s life sciences innovation ecosystem upon its early 2027 completion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219467591/en/
Set to complete in 2027, the state-of-the-art iREACH Health clinical research center is set to become a cornerstone of Northern Ireland's life sciences landscape. As part of this development, Celerion will relocate its U.K. Phase 1 clinical research operations to the facility, positioning it at the forefront of clinical research innovation. (Photo: Business Wire)
Celerion’s Belfast clinic has a history of clinical research excellence spanning more than 30 years, marked by continual growth, expanding capabilities, and strong partnerships with academic and medical institutions. Relocating to iREACH Health positions Celerion at the forefront of clinical research innovation, facilitating collaboration across government, industry, and academia to advance novel therapies for patients in need.
iREACH Health will be situated across two buildings beside Belfast City Hospital. The clinical research innovation center will include a 100-bed Phase 1 facility designed to Celerion’s specifications, equipped to support its U.K. team, including a highly experienced full-service data management, medical writing, and biometrics group. This team of early development experts specializes in adaptive study design, protocol development, clinical data sciences, PK/PD analysis, and statistical reporting delivering data-driven insights that reduce risk and optimize trial outcomes.
“We’re thrilled to build on our long-standing relationship with Queen’s University Belfast by relocating to this world-class center,” said Phil Bach, Celerion’s Executive Vice President of Global Clinical Research. “Our new home at iREACH Health will enhance the speed and efficiency of our Phase 1 clinical trials, supporting our clients in accelerating drug development timelines.”
Professor Judy Bradley, CEO of iREACH Health, highlighted the innovation center’s vision: “Our aim is to deliver agile, people-centered clinical trials that are innovative, data-driven, and digitally enabled. We are delighted to work with Celerion to advance those plans and tackle some of Northern Ireland’s most pressing healthcare challenges. This partnership with Celerion will help deliver significant benefits for the region and beyond, driving advancements in healthcare whilst supporting economic and social outcomes.”
About Celerion
Celerion, a global leader in early clinical research, offers clients expert-driven services that enable fast, informed decisions in drug development. With over 50 years of experience, Celerion specializes in Phase 1 studies, including first-in-human dose escalation, drug-drug interactions, cardiac safety, bioequivalence, metabolism, and pharmacokinetics in patient populations. Celerion also provides comprehensive data management, biostatistics, clinical monitoring, and bioanalytical services. For more information, visit www.celerion.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219467591/en/
Contacts
Michelle Maklas-Baker
Associate Director, Global Marketing
+1 732-306-7804
michelle.maklasbaker@celerion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom